RxDoctor Payments Data

Sandy Park, MD

Cardiovascular Disease · Rancho Mirage, CANPI 1134462039

Payments from drug & device makers

$8,654in general payments, 2019–2025

Across 37 payments — averaging $233.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$6K
  • Abbott$2K
  • E.r. Squibb & Sons, L.L.C.$140
  • Bridgebio Pharma, Inc.$135
  • Esperion Therapeutics, Inc.$125
  • Bayer$123
  • plus $375 from 7 others

What the payments were for

  • Travel & lodging$1,04941%
  • Food & beverage$1,51759%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,654 in reported general payments places this provider in the 70th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$478,494
Medicare patients
2,301
Services billed
10,578

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis26$557,933
EliquisApixaban305$380,416
JardianceEmpagliflozin129$155,685
EntrestoSacubitril/Valsartan98$108,402
XareltoRivaroxaban81$104,551
FarxigaDapagliflozin Propanediol41$40,473
Repatha SureclickEvolocumab33$39,812
VascepaIcosapent Ethyl29$15,243
OzempicSemaglutide18$14,619
Metoprolol Succinate541$9,146
Rosuvastatin Calcium401$6,501
Ezetimibe233$6,373
Atorvastatin Calcium434$4,180
Amlodipine Besylate384$2,506
Losartan Potassium212$2,392

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$58$938,349331 claims
NovartisEntresto$22$108,40298 claims
Johnson & JohnsonXarelto$41$104,55181 claims
AstraZenecaFarxiga$20$40,47341 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Rancho Mirage

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →